These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17086939)

  • 1. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
    Tomlinson B
    Curr Opin Investig Drugs; 2006 Oct; 7(10):936-45. PubMed ID: 17086939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M; Tomlinson B
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1143-50. PubMed ID: 20872317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
    Spooner LM; Olin JL
    Ann Pharmacother; 2012 Feb; 46(2):240-7. PubMed ID: 22298602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good results for lipodystrophy drug.
    AIDS Patient Care STDS; 2007 Feb; 21(2):146. PubMed ID: 17328664
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
    Falutz J; Allas S; Mamputu JC; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
    AIDS; 2008 Sep; 22(14):1719-28. PubMed ID: 18690162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
    Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4291-304. PubMed ID: 20554713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: SB-485232, GlaxoSmithKline.
    Golab J; Stoklosa T
    Curr Opin Mol Ther; 2005 Feb; 7(1):85-93. PubMed ID: 15732534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on tesamorelin in HIV-associated lipodystrophy.
    Dhillon S
    BioDrugs; 2011 Dec; 25(6):405-8. PubMed ID: 22050344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tesamorelin.
    Grunfeld C; Dritselis A; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Feb; 10(2):95-6. PubMed ID: 21283099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.
    Falutz J
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):517-29. PubMed ID: 21663844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1034-47. PubMed ID: 18729010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
    Dhillon S
    Drugs; 2011 May; 71(8):1071-91. PubMed ID: 21668043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects and complications. Clinical trials of tesamorelin in Canada.
    TreatmentUpdate; 2007; 19(3):7. PubMed ID: 17571443
    [No Abstract]   [Full Text] [Related]  

  • 14. Side effects and complications. Tesamorelin--results from Phase III.
    TreatmentUpdate; 2007; 19(3):6-7. PubMed ID: 17575575
    [No Abstract]   [Full Text] [Related]  

  • 15. Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
    Berger D
    Posit Aware; 2008; 19(3):31. PubMed ID: 18724445
    [No Abstract]   [Full Text] [Related]  

  • 16. CJC-1131. ConjuChem.
    Giannoukakis N
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1245-9. PubMed ID: 14649218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tesamorelin, a human growth hormone releasing factor analogue.
    Wang Y; Tomlinson B
    Expert Opin Investig Drugs; 2009 Mar; 18(3):303-10. PubMed ID: 19243281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VasoCare. Vasogen.
    Visioli F
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1247-9. PubMed ID: 11717811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RDP-58 (SangStat Medical).
    Holtmann MM
    IDrugs; 2003 Dec; 6(12):1188-94. PubMed ID: 14666431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approves tesamorelin for HIV-related lipodystrophy.
    Traynor K
    Am J Health Syst Pharm; 2010 Dec; 67(24):2082. PubMed ID: 21115997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.